COMMUNIQUÉS West-GlobeNewswire
-
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
21/10/2025 -
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
21/10/2025 -
Phonak’s AI revolution continues: new Infinio Ultra hearing aids with clearer sound and easier maintenance
21/10/2025 -
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
21/10/2025 -
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
21/10/2025 -
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
21/10/2025 -
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
21/10/2025 -
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
21/10/2025 -
Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference
21/10/2025 -
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
20/10/2025 -
EMS HEALTH LLC Unveils New E-Commerce Platform NuGeneLabs.com for Holistic Wellness
20/10/2025 -
BRAVE Trauma Therapist Collective Celebrates 3 Years as Leading Community for Trauma Therapists
20/10/2025 -
Hapbee Announces R&D of Three New Frequency Wellness Signals for Hunger Management, Allergy Comfort, and Sexual Vitality; Closes Private Placement and Appoints Director
20/10/2025 -
Aurora Spine Announces Proposed Warrant Extension
20/10/2025 -
Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA
20/10/2025 -
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
20/10/2025 -
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
20/10/2025 -
Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
20/10/2025 -
Health Catalyst to Announce Third Quarter 2025 Operating Results and Host Conference Call on Monday, November 10, 2025
20/10/2025
Pages